# US 2025/0207136 A1 · Use of Telomerase Inhibitors for the Treatment of Myeloproliferative Disorders and Myeloproliferative Neoplasms

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0207136 A1
- Document ID: US20250207136A1
- Status: Published application
- Kind: A1
- Application number: 18/970,086
- Filed: 2024-12-05
- Published: 2025-06-26
- Earliest claimed: 2012-12-07
- Assignees: Geron Corporation
- Applicants: Geron Corporation
- Inventors: Monic J. Stuart; Stephen Kelsey
- Web page: https://patentgrep.com/patent/US20250207136A1

## CPC

- C12N 15/1135: {against oncogenes or tumor suppressor genes}
- A61K 47/543: {Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine}
- A61K 47/549: {Sugars, nucleosides, nucleotides or nucleic acids}
- A61K 49/0423: {Nanoparticles, nanobeads, nanospheres, nanocapsules, i.e. having a size or diameter smaller than 1 micrometer}
- B82Y 5/00: Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
- C12N 2320/30: Special therapeutic applications
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- B82Y: SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES

## Abstract

Provided herein are methods for reducing neoplastic progenitor cell proliferation and alleviating symptoms associated in individuals diagnosed with or thought to have Essential Thrombocythemia (ET). Also provided herein are methods for using telomerase inhibitors for maintaining blood platelet counts at relatively normal ranges in the blood of individuals diagnosed with or suspected of having ET.

## Claims

### Claim at position 1

-41. (canceled)

### Claim 42

A method for treating myelodysplastic syndrome (MDS) in a human, the method comprising:
administering an intravenous infusion of a therapeutically effective amount of imetelstat to the human, wherein the human has transfusion-dependent anemia and wherein the administering is effective to treat MDS in the human.

### Claim 43 (depends on 42)

The method of claim 42, wherein the human is resistant or intolerant to a prior non-telomerase inhibitor-based therapy.

### Claim 44 (depends on 42)

The method of claim 42, wherein the therapeutically effective amount of imetelstat is administered to the human every four weeks.

### Claim 45 (depends on 42)

The method of claim 42, wherein the imetelstat is administered with a pharmaceutically acceptable excipient.

### Claim 46

A method for treating myelodysplastic syndrome (MDS) in a human, the method comprising:
administering an intravenous infusion of a therapeutically effective amount of imetelstat to the human every four weeks, wherein the human has transfusion-dependent anemia and wherein the administering is effective to treat MDS in the human.

### Claim 47 (depends on 46)

The method of claim 46, wherein the imetelstat is administered with a pharmaceutically acceptable excipient.

### Claim 48

A method for alleviating at least one symptom associated with myelodysplastic syndrome (MDS) in a human in need thereof, the method comprising administering an intravenous infusion of a therapeutically effective amount of imetelstat to the human, wherein administration of the imetelstat alleviates at least one symptom associated with MDS.

### Claim 49 (depends on 48)

The method of claim 48, wherein the human is resistant to or intolerant to a prior non-telomerase inhibitor-based therapy.

### Claim 50 (depends on 48)

The method of claim 48, wherein the imetelstat is administered with a pharmaceutically acceptable excipient.

### Claim 51 (depends on 48)

The method of claim 48, wherein the imetelstat is administered every four weeks.
